The FKBP6 antibody targets the FK506-binding protein 6 (FKBP6), a member of the FKBP family characterized by peptidyl-prolyl isomerase (PPIase) activity. FKBP6 is involved in protein folding, chromatin remodeling, and regulation of cellular signaling pathways. It plays a critical role in male fertility by participating in homologous chromosome pairing during meiosis. Additionally, FKBP6 is implicated in genomic imprinting disorders, as its gene resides within the Prader-Willi/Angelman syndrome-critical region on chromosome 15. Deletions or mutations in FKBP6 are associated with Prader-Willi syndrome and oligozoospermia.
The FKBP6 antibody is widely used in research to study its expression, localization, and interactions in tissues, particularly in the testis, brain, and cancer cells. It aids in elucidating FKBP6's role in spermatogenesis, neurological development, and tumor progression. Commercial FKBP6 antibodies are typically raised against recombinant protein fragments or synthetic peptides, validated via Western blot, immunohistochemistry, and immunofluorescence. Cross-reactivity with other FKBP family members is a key consideration during experimental design. Recent studies also explore FKBP6's potential as a biomarker in cancers, such as ovarian and lung adenocarcinoma, where dysregulated expression correlates with prognosis. This antibody remains a vital tool for dissecting FKBP6's multifunctional biology and its implications in human diseases.